Quarterly Performance Highlights Vertex reported total revenue of $2.77 billion for Q1 2025, representing modest year-over-year growth compared to Q1 2024.

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile, the ...

Vertex Pharmaceuticals Incorporated VRTX stock has declined 8.9% in the past three months. The deterioration was due to soft first-quarter results, slower-than-expected uptake of its newer drugs ...

The results were reported late last week at an annual scientific meeting of liver specialists. Vertex shares were down 14% at $24.93. Show Conversation (0) Partner Center ...

Vertex reported total revenue of $2.77 billion for Q1 2025, representing modest year-over-year growth compared to Q1 2024. The company’s flagship cystic fibrosis treatment TRIKAFTA/KAFTRIO generated ...